anaprazole
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jun 16, 2015 (NCT04463173)
Timeline
Indications
Mechanism of action
- Cytochrome P450 19A1INHIBITOR
CYP19A1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COCCCOc1cccc(C[S+]([O-])c2nc3cc4c(cc3[nH]2)OCC4)c1C- Mol. weight
- 400.5 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4651083 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07010107 | Phase 3 | Jul 30, 2025 | Xuanzhu Biopharmaceutical Co., Ltd. |
| NCT04476394 | Phase 1 | Aug 3, 2020 | Sihuan Pharmaceutical Holdings Group Ltd. |
| NCT04471922 | Phase 1 | Mar 21, 2019 | Sihuan Pharmaceutical Holdings Group Ltd. |
| NCT04466748 | Phase 1 | Sep 8, 2015 | Sihuan Pharmaceutical Holdings Group Ltd. |
| NCT04463173 | Phase 1 | Jun 16, 2015 | Sihuan Pharmaceutical Holdings Group Ltd. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sihuan Pharmaceutical Holdings Group Ltd. | For profit | 4 | 4 | 1 | 2015 |
| Xuanzhu Biopharmaceutical Co., Ltd. | For profit | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1